首页> 外文期刊>Archives of medical research >Protein Kinase A as a Promising Target for Heart Failure Drug Development
【24h】

Protein Kinase A as a Promising Target for Heart Failure Drug Development

机译:蛋白激酶A作为心力衰竭药物发育的有希望的目标

获取原文
获取原文并翻译 | 示例
           

摘要

Heart failure (HF) is a clinical syndrome characterized by impaired ability of the heart to fill or eject blood. HF is rather prevalent and it represents the foremost reason of hospitalization in the United States. The costs linked to HF overrun those of all other causes of disabilities, and death in the United States and all over the developed as well as the developing countries which amplify the supreme significance of its prevention. Protein kinase (PK) A plays multiple roles in heart functions including, contraction, metabolism, ion fluxes, and gene transcription. Altered PKA activity is likely to cause the progression to cardiomyopathy and HF. Thus, this review is intended to focus on the roles of PKA and PKA-mediated signal transduction in the healthy heart as well as during the development of HF. Furthermore, the impact of cardiac PKA inhibition/activation will be highlighted to identify PKA as a potential target for the HF drug development.
机译:心力衰竭(HF)是一种临床综合征,其特征在于心脏填充或喷射血液的损害能力。 HF相当普遍,它代表了美国住院的最重要原因。 与HF联系的成本超越了所有其他残疾原因的成本,以及美国的死亡以及发达国家以及发展中国家,并扩大了预防至高无上的重要意义。 蛋白激酶(PK)A在心脏功能中发挥多种作用,包括收缩,代谢,离子助熔剂和基因转录。 改变的PKA活性可能导致心肌病和HF的进展。 因此,本综述旨在专注于PKA和PKA介导的信号转导在健康心脏以及在HF的发育期间的作用。 此外,将强调心脏PKA抑制/活化的影响以鉴定PKA作为HF药物发育的潜在目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号